Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2

Area of Science:

• Biochemistry
• Cardiology
• Toxicology

Background:

• Doxorubicin (Dox) is an effective anticancer drug, but its use is limited by severe cardiac toxicity.
• Metallothionein (MT) is known to mitigate Dox-induced cardiotoxicity.
• Uncoupling proteins (UCPs) were identified as potential mediators in MT's protective mechanism.

Purpose of the Study:

• To elucidate the mechanisms by which MT protects against Dox-induced cardiotoxicity.
• To investigate the relationship between MT and uncoupling protein 2 (UCP2).

Main Methods:

• In vivo studies using wild-type and MT-I/II null mice treated with Dox.
• In vitro studies with isolated cardiomyocytes pretreated with antioxidants or UCP2 inhibitors before Dox exposure.
• Proteomics and co-immunoprecipitation assays to determine protein interactions and expression levels.

Main Results:

• Doxorubicin treatment led to significantly lower UCP2 levels in MT-null mice compared to wild-type mice.
• Inhibition of UCP2 (using genipin) exacerbated Dox-induced oxidative injury, especially in MT-null cardiomyocytes.
• MT did not directly bind to UCP2, but antioxidants and Nrf2 activators prevented Dox-induced decreases in UCP2 expression.

Conclusions:

• UCP2 plays a crucial role in mediating MT's protective effects against Dox-induced cardiotoxicity by attenuating free radical damage.
• MT likely regulates UCP2 expression through the Nrf2 pathway, rather than direct physical interaction.
• These findings highlight a novel mechanism involving MT, UCP2, and Nrf2 in mitigating chemotherapy-induced cardiac damage.